Boston Scientific faces risks due to market concerns and global trade tensions, but remains optimistic.

From Zacks Investment Research: 2025-03-25 04:18:00

Boston Scientific (BSX) is experiencing a temporary decline in March due to broader market concerns and the Fed’s cautious stance on interest rates. The company faces risks from global trade tensions, especially with operations in China and Europe. Despite this, BSX has outperformed its industry peers and remains optimistic about its financial performance. The company expects solid revenue growth in 2025 driven by expanding portfolios and global strategies. Analysts see a strong upside potential for BSX with an average target price of $118.57, reinforcing its attractiveness as a Buy. BSX continues to gain market share in core businesses and is poised for growth in 2025.



Read more at Zacks Investment Research: The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic – March 25, 2025